Latest PEGylation Stories

NOVATO, Calif., Aug. 2 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today an update in the Phase 2 clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of phenylketonuria (PKU). Data reported in this announcement reflect preliminary results as of July 23, 2010. Complete top-line results are expected in the fourth quarter of 2010. Key highlights of the study: 23 adult patients have been enrolled in the study, and...

SINGAPORE, June 24 /PRNewswire/ -- Regular blood screening conducted in hospitals for at-risk patients, particularly injecting drug users (IDUs), has expanded the patient base and enhanced prospects for the hepatitis C therapeutics market in Indonesia. Moreover, increasing health awareness in Indonesia has encouraged the population (mostly urban) to opt for annual physical examinations and regular blood screening that enable the detection of Hepatitis C. (Logo:...

SINGAPORE, May 6 /PRNewswire/ -- As concerted efforts to raise disease awareness have expanded the number of diagnosed cases, the hepatitis C therapeutics market in Taiwan is beginning to witness steady growth. Nearly 50 percent of patients with hepatitis C virus (HCV) genotype 1 require treatment; and this is the most prevalent type in Taiwan. However, factors such as dosage frequency, severity of side effects, and low efficacy have often resulted in noncompliance of extended treatment....

Extending hepatitis C treatment for liver transplant patients beyond current standards results in high clearance rates of the hepatitis C virus from the blood, and a low relapse rate, according to a study by Henry Ford Hospital."We found that patients who achieved a sustained virological response were more likely to have had extended treatment after transplant," says Matthew Moeller, M.D., gastroenterology fellow at Henry Ford Hospital and lead author of the study."In the...

SAN CARLOS, Calif., April 27 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2010 on Wednesday, May 5, 2010, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). The press release and a live audio-only Webcast of the conference call can...

BETHLEHEM, Pa., April 13 /PRNewswire/ -- Particle Sciences Inc. (PSI), a leading pharmaceutical CRO, is adding to its portfolio of drug delivery technologies through the acquisition of a versatile PEG-based technology. The technology covers a series of PEG-grafted cationic polymers that have a wide variety of applications in the pharmaceutical arena. According to Robert Lee, Particle Sciences' VP Pharmaceutical Development, "PEGylation is a recognized approach to stabilize drug...

SAN CARLOS, Calif., Feb. 23 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year ended December 31, 2009 on Tuesday, March 2, 2010, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). The press release and a live audio-only Webcast of the...

PRINCETON, N.J., Feb. 17 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the complete enrollment by Roche of the 12 week RG7128 Phase 2b study (PROPEL) of approximately 400 treatment-naive patients with hepatitis C virus (HCV) genotypes 1 and 4. The study remains blinded to Roche and Pharmasset. Roche has initiated a 24 week Phase 2b study with RG7128 in combination with pegylated interferon and ribavirin in treatment-naïve patients with HCV genotypes 1 and 4...

SAN DIEGO, Jan. 28 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys®) and ribavirin (Copegus®) in refractory HCV patients. Antiviral activity, safety and tolerability of the triple combination will be assessed after up to 48 weeks of therapy. "There is a significant unmet medical need in HCV patients who have not responded to pegylated interferon and...

WALTHAM, Mass., Jan. 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that U.S. gastroenterologists will treat a larger proportion of treatment nonresponder hepatitis C patients with Vertex/Tibotec/Mitsubishi Tanabe's telaprevir than Merck's boceprevir. U.S. gastroenterologists indicate that they would prescribe telaprevir to 50 percent of their hepatitis C non-responder patients. Telaprevir is...